Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Equities research analysts at Leerink Swann increased their Q1 2018 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research report issued to clients and investors on Thursday, according to Zacks Investment Research. Leerink Swann analyst M. Schmidt now forecasts that the biopharmaceutical company will earn ($1.61) per share for the quarter, up from their prior forecast of ($1.67). Leerink Swann also issued estimates for Agios Pharmaceuticals’ Q2 2018 earnings at ($1.44) EPS, Q3 2018 earnings at ($1.42) EPS, Q4 2018 earnings at ($1.34) EPS, FY2018 earnings at ($5.78) EPS, FY2019 earnings at ($4.41) EPS and FY2020 earnings at ($2.88) EPS.
AGIO has been the topic of a number of other reports. Oppenheimer downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 price objective for the company in a report on Tuesday, January 16th. Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 12th. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Cann reiterated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Agios Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $85.50.
Agios Pharmaceuticals (AGIO) traded down $0.17 on Monday, hitting $83.33. 237,701 shares of the stock were exchanged, compared to its average volume of 450,344. Agios Pharmaceuticals has a one year low of $45.11 and a one year high of $85.88. The firm has a market cap of $4,780.00, a P/E ratio of -12.36 and a beta of 2.02.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The company had revenue of $9.80 million during the quarter, compared to analyst estimates of $12.65 million. During the same quarter in the previous year, the business posted ($1.34) earnings per share. The company’s revenue for the quarter was down 56.7% on a year-over-year basis.
A number of institutional investors have recently added to or reduced their stakes in AGIO. Alliancebernstein L.P. raised its holdings in Agios Pharmaceuticals by 16.3% during the 2nd quarter. Alliancebernstein L.P. now owns 21,742 shares of the biopharmaceutical company’s stock worth $1,119,000 after purchasing an additional 3,050 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Agios Pharmaceuticals by 21.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 49,994 shares of the biopharmaceutical company’s stock worth $2,572,000 after purchasing an additional 8,965 shares during the last quarter. Northern Trust Corp raised its holdings in Agios Pharmaceuticals by 31.3% during the 2nd quarter. Northern Trust Corp now owns 232,802 shares of the biopharmaceutical company’s stock worth $11,977,000 after purchasing an additional 55,560 shares during the last quarter. California Public Employees Retirement System raised its holdings in Agios Pharmaceuticals by 2.3% during the 2nd quarter. California Public Employees Retirement System now owns 34,900 shares of the biopharmaceutical company’s stock worth $1,796,000 after purchasing an additional 800 shares during the last quarter. Finally, Ark Investment Management LLC raised its holdings in Agios Pharmaceuticals by 66.2% during the 2nd quarter. Ark Investment Management LLC now owns 10,713 shares of the biopharmaceutical company’s stock worth $551,000 after purchasing an additional 4,267 shares during the last quarter. Hedge funds and other institutional investors own 82.40% of the company’s stock.
In other Agios Pharmaceuticals news, insider Carman Alenson sold 2,150 shares of the firm’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $75.00, for a total transaction of $161,250.00. Following the completion of the transaction, the insider now owns 2,150 shares in the company, valued at approximately $161,250. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $83.08, for a total transaction of $249,240.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 191,180 shares of company stock valued at $14,758,309. Company insiders own 5.43% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Q1 2018 EPS Estimates for Agios Pharmaceuticals Inc (AGIO) Lifted by Analyst” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://ledgergazette.com/2018/03/15/leerink-swann-equities-analysts-boost-earnings-estimates-for-agios-pharmaceuticals-inc-agio.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.